Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

visilizumab

(vih-sih-LIZ-yoo-mab)
A substance being studied in the treatment of an immune system reaction called graft-versus-host disease (GVHD), which may occur after a donor stem cell transplant. It is also being studied in the treatment of some autoimmune diseases. Visilizumab binds to a protein called CD3, which is found on some T cells (a type of white blood cell). This may help suppress the body’s immune response. Visilizumab is a type of monoclonal antibody.
Search NCI's Dictionary of Cancer Terms